{"nctId":"NCT04115488","briefTitle":"Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®","startDateStruct":{"date":"2019-10-01","type":"ACTUAL"},"conditions":["Relapsing-Remitting Multiple Sclerosis (RRMS)"],"count":265,"armGroups":[{"label":"PB006","type":"EXPERIMENTAL","interventionNames":["Biological: Intravenous (IV) infusions"]},{"label":"Tysabri","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Intravenous (IV) infusions"]}],"interventions":[{"name":"Intravenous (IV) infusions","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients (age ≥18 to 60 years), with relapsing-remitting multiple sclerosis (RRMS) defined by the 2010 revised McDonald criteria\n* At least 1 documented relapse within the previous year and either ≥1 GdE T1-weighted brain lesions or ≥9 T2-weighted brain lesions at Screening\n* Kurtzke Expanded Disability Status Scale (EDSS) score from 0 to 5 (inclusive) at Screening\n\nExclusion Criteria:\n\n* Manifestation of multiple sclerosis (MS) other than relapsing-remitting multiple sclerosis (RRMS)\n* Relapse within the 30 days prior Screening and until administration of the first dose of study drug\n* Prior treatment with natalizumab, alemtuzumab, ocrelizumab, daclizumab, rituximab, cladribine, or other B- and T-cell targeting therapies\n* Prior total lymphoid irradiation or bone marrow or organ transplantation\n* Patients with John Cunningham Virus (JCV) index \\>1.5 at Screening\n* Past or current Progressive Multi-focal leukoencephalopathy (PML) diagnosis\n* Severe renal function impairment as defined by serum creatinine values \\>120 micromol per litre","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Number of New Active Lesions Over 24 Weeks","description":"Cumulative number of new active lesions over 24 weeks, calculated as the sum of all new gadolinium-enhancing (GdE) T1-weighted and new/enlarging T2-weighted lesion. Assessment was performed using Magnetic Resonance Imaging (MRI). Identification of GdE T1-weighted and T2-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"3.73"},{"groupId":"OG001","value":"1.9","spread":"3.97"},{"groupId":"OG002","value":"1.4","spread":"3.65"},{"groupId":"OG003","value":"2.1","spread":"3.78"},{"groupId":"OG004","value":"1.9","spread":"4.09"}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of New Active Lesions Over 48 Weeks","description":"Cumulative number of new active lesions over 48 weeks, calculated as the sum of all new gadolinium-enhancing (GdE) T1-weighted and new/enlarging T2-weighted lesion. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of GdE T1-weighted lesions and T2-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center. A macrocyclic Gd-based contrast agent was administered as an Intravenous infusion of 0.1 Millimole per kilogram \\[mmol/kg\\].","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"3.72"},{"groupId":"OG001","value":"2.3","spread":"5.68"},{"groupId":"OG002","value":"1.5","spread":"3.75"},{"groupId":"OG003","value":"2.1","spread":"3.82"},{"groupId":"OG004","value":"2.3","spread":"5.70"}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of New GdE T1-weighted Lesions Over 24 Weeks","description":"Cumulative number of new GdE T1-weighted lesions over 24 weeks, calculated as the sum of all new gadolinium-enhancing (GdE) T1-weighted. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of GdE T1-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center. A macrocyclic Gd-based contrast agent (gadobutrol, gadoteric acid, or gadoteridol) was to be administered as an Intravenous infusion of 0.1 Millimole per kilogram \\[mmol/kg\\].","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.01"},{"groupId":"OG001","value":"0.4","spread":"1.25"},{"groupId":"OG002","value":"0.3","spread":"1.02"},{"groupId":"OG003","value":"0.4","spread":"0.81"},{"groupId":"OG004","value":"0.4","spread":"1.37"}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of New GdE T1-weighted Lesions Over 48 Weeks","description":"Cumulative number of new GdE T1-weighted lesions over 48 weeks, calculated as the sum of all new gadolinium-enhancing (GdE) T1-weighted. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of GdE T1-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center. A macrocyclic Gd-based contrast agent (gadobutrol, gadoteric acid, or gadoteridol) was to be administered as an Intravenous infusion of 0.1 Millimole per kilogram \\[mmol/kg\\].","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.02"},{"groupId":"OG001","value":"0.4","spread":"1.39"},{"groupId":"OG002","value":"0.3","spread":"1.03"},{"groupId":"OG003","value":"0.4","spread":"0.82"},{"groupId":"OG004","value":"0.4","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Without New GdE T1-weighted Lesions Over 24 Weeks","description":"Number of patients without new GdE T1-weighted lesions over 24 weeks. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of GdE T1-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center. A macrocyclic Gd-based contrast agent (gadobutrol, gadoteric acid, or gadoteridol) was to be administered as an Intravenous infusion of 0.1 Millimole per kilogram \\[mmol/kg\\].","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"105","spread":null},{"groupId":"OG003","value":"23","spread":null},{"groupId":"OG004","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Without New GdE T1-weighted Lesions Over 48 Weeks","description":"Number of patients without new GdE T1-weighted lesions over 48 weeks. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of GdE T1-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center. A macrocyclic Gd-based contrast agent (gadobutrol, gadoteric acid, or gadoteridol) was to be administered as an Intravenous infusion of 0.1 Millimole per kilogram \\[mmol/kg\\].","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"102","spread":null},{"groupId":"OG003","value":"22","spread":null},{"groupId":"OG004","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of New/Enlarging T2-weighted Lesions Over 24 Weeks","description":"Cumulative number of new/enlarging T2-weighted lesions over 24 weeks. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of T2-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"3.79"},{"groupId":"OG001","value":"2.0","spread":"4.12"},{"groupId":"OG002","value":"1.5","spread":"3.83"},{"groupId":"OG003","value":"2.2","spread":"3.84"},{"groupId":"OG004","value":"2.0","spread":"4.25"}]}]}]},{"type":"SECONDARY","title":"Cumulative Number of New/Enlarging T2-weighted Lesions Over 48 Weeks","description":"Cumulative number of new/enlarging T2-weighted lesions over 48 weeks. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of T2-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.09"},{"groupId":"OG001","value":"2.4","spread":"5.79"},{"groupId":"OG002","value":"1.6","spread":"3.93"},{"groupId":"OG003","value":"2.2","spread":"3.89"},{"groupId":"OG004","value":"2.5","spread":"5.81"}]}]}]},{"type":"SECONDARY","title":"Number of Persistent Lesions After 24 Weeks","description":"Number of persistent lesions after 24 weeks. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of GdE T1-weighted lesions and T2-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center. A macrocyclic Gd-based contrast agent (gadobutrol, gadoteric acid, or gadoteridol) was to be administered as an Intravenous infusion of 0.1 Millimole per kilogram \\[mmol/kg\\].","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"2.46"},{"groupId":"OG001","value":"0.4","spread":"2.92"},{"groupId":"OG002","value":"0.5","spread":"2.49"},{"groupId":"OG003","value":"0.1","spread":"0.31"},{"groupId":"OG004","value":"0.6","spread":"3.37"}]}]}]},{"type":"SECONDARY","title":"Number of Persistent Lesions After 48 Weeks","description":"Number of persistent lesions after 48 weeks. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of GdE T1-weighted lesions and T2-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center. A macrocyclic Gd-based contrast agent (gadobutrol, gadoteric acid, or gadoteridol) was to be administered as an Intravenous infusion of 0.1 Millimole per kilogram \\[mmol/kg\\].","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"2.55"},{"groupId":"OG001","value":"0.6","spread":"3.35"},{"groupId":"OG002","value":"0.5","spread":"2.58"},{"groupId":"OG003","value":"0.1","spread":"0.26"},{"groupId":"OG004","value":"0.6","spread":"3.37"}]}]}]},{"type":"SECONDARY","title":"Annualized Relapse Rate After 24 Weeks","description":"Annualized relapse rate after 24 weeks. Relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality had to be present for at least 24 hours and have occurred in the absence of fever or infection. Annualized relapse rate: A: Number of medically confirmed relapses overall. B: Duration of follow-up time overall, where follow-up time was defined as: (last day of follow-up - day of randomization + 1) / 365.25. The ratio of relapses per patient-year: A/B. Annualized Relapse Rate was calculated across the entire group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.206","spread":null},{"groupId":"OG001","value":"0.152","spread":null},{"groupId":"OG002","value":"0.194","spread":null},{"groupId":"OG003","value":"0.143","spread":null},{"groupId":"OG004","value":"0.114","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Relapse Rate After 48 Weeks","description":"Annualized relapse rate after 48 weeks. Relapse was defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality had to be present for at least 24 hours and have occurred in the absence of fever or infection. Annualized relapse rate: A: Number of medically confirmed relapses overall. B: Duration of follow-up time overall, where follow-up time was defined as: (last day of follow-up - day of randomization + 1) / 365.25. The ratio of relapses per patient-year: A/B. Annualized Relapse Rate was calculated across the entire group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.174","spread":null},{"groupId":"OG001","value":"0.133","spread":null},{"groupId":"OG002","value":"0.168","spread":null},{"groupId":"OG003","value":"0.146","spread":null},{"groupId":"OG004","value":"0.113","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Expanded Disability Status Scale (EDSS) After 24 Weeks","description":"Change from baseline in Expanded Disability Status Scale (EDSS) after 24 weeks. The Kurtzke EDSS, commonly used to evaluate the degree of neurologic impairment in multiple sclerosis (MS), is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments. Based on a standard neurological examination, the 7 functional systems (plus \"other\") are rated. These ratings are then used in conjunction with observations and information concerning gait and use of assistive devices to rate the EDSS. EDSS ratings were performed by independent examining neurologists. After re-randomization, Week 24 is considered baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.211"},{"groupId":"OG001","value":"0.00","spread":"0.354"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Expanded Disability Status Scale (EDSS) After 48 Weeks","description":"Change from baseline in Expanded Disability Status Scale (EDSS) after 48 weeks. The Kurtzke EDSS, commonly used to evaluate the degree of neurologic impairment in MS, is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments. Based on a standard neurological examination, the 7 functional systems (plus \"other\") are rated. These ratings are then used in conjunction with observations and information concerning gait and use of assistive devices to rate the EDSS. EDSS ratings were performed by independent examining neurologists.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.536"},{"groupId":"OG001","value":"-0.05","spread":"0.443"},{"groupId":"OG002","value":"-0.10","spread":"0.498"},{"groupId":"OG003","value":"-0.03","spread":"0.325"},{"groupId":"OG004","value":"-0.02","spread":"0.312"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Anti-drug (Natalizumab) Antibodies (ADA) and Persistent Antibodies After 24 Weeks","description":"Percentage of subjects with anti-drug (natalizumab) antibodies (ADA) and persistent antibodies after 24 weeks. A positive ADA patient was defined as a patient who had at least 1 positive ADA result in any post-baseline sample. A persistently positive ADA patient was defined as a patient with confirmed positive ADAs in 2 or more consecutive positive ADA samples at post-dose visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"27.2","spread":null},{"groupId":"OG002","value":"28.7","spread":null},{"groupId":"OG003","value":"43.3","spread":null},{"groupId":"OG004","value":"22.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"29.6","spread":null},{"groupId":"OG002","value":"30.3","spread":null},{"groupId":"OG003","value":"43.3","spread":null},{"groupId":"OG004","value":"25.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Anti-drug (Natalizumab) Antibodies (ADA) and Persistent Antibodies After 48 Weeks","description":"Percentage of subjects with anti-drug (natalizumab) antibodies (ADA) and persistent antibodies after 48 weeks. A positive ADA patient was defined as a patient who had at least 1 positive ADA result in any post-baseline sample. A persistently positive ADA patient was defined as a patient with confirmed positive ADAs in 2 or more consecutive positive ADA samples at post-dose visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"11.6","spread":null},{"groupId":"OG002","value":"10.4","spread":null},{"groupId":"OG003","value":"17.9","spread":null},{"groupId":"OG004","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"11.6","spread":null},{"groupId":"OG002","value":"11.3","spread":null},{"groupId":"OG003","value":"17.9","spread":null},{"groupId":"OG004","value":"9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Neutralizing Antibodies After 24 Weeks","description":"Percentage of subjects with positive (transient and persistent) neutralizing antibodies after 24 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6","spread":null},{"groupId":"OG001","value":"64.9","spread":null},{"groupId":"OG002","value":"67.6","spread":null},{"groupId":"OG003","value":"61.5","spread":null},{"groupId":"OG004","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Neutralizing Antibodies After 48 Weeks","description":"Percentage of subjects with positive (transient and persistent) neutralizing antibodies after 48 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"61.5","spread":null},{"groupId":"OG003","value":"60.0","spread":null},{"groupId":"OG004","value":"44.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Treatment-Emergent Adverse Event (TEAE) or Any Treatment-Emergent Serious Adverse Event (SAE) After 24 Weeks","description":"Number of subjects with any Treatment-Emergent Adverse Event (TEAE) or any Treatment-Emergent Serious Adverse Event (SAE) after 24 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Treatment-Emergent Adverse Event (TEAE) or Any Treatment-Emergent Serious Adverse Event (SAE) After 48 Weeks","description":"Number of subjects with any Treatment-Emergent Adverse Event (TEAE) or any Treatment-Emergent Serious Adverse Event (SAE) after 48 weeks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Natalizumab Trough Concentration (Ctrough) Over Time, Week 8","description":"Natalizumab trough concentration (Ctrough) over time, week 8. Serum samples were collected prior to treatment. Sample was taken prior to treatment for each patient.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26804.75","spread":"12949.541"},{"groupId":"OG001","value":"25010.49","spread":"12557.895"}]}]}]},{"type":"SECONDARY","title":"Natalizumab Trough Concentration (Ctrough) Over Time, Week 16","description":"Natalizumab trough concentration (Ctrough) over time, week 16. Serum samples were collected prior to treatment. Sample was taken prior to treatment for each patient.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33872.92","spread":"18151.190"},{"groupId":"OG001","value":"32543.28","spread":"14636.925"}]}]}]},{"type":"SECONDARY","title":"Natalizumab Trough Concentration (Ctrough) Over Time, Week 24","description":"Natalizumab trough concentration (Ctrough) over time, week 24. Serum samples were collected prior to treatment. Sample was taken prior to treatment for each patient.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36853.93","spread":"15292.389"},{"groupId":"OG001","value":"35617.65","spread":"16049.669"}]}]}]},{"type":"SECONDARY","title":"Natalizumab Trough Concentration (Ctrough) Over Time, Week 32","description":"Natalizumab trough concentration (Ctrough) over time, week 32. Serum samples were collected prior to treatment. Sample was taken prior to treatment for each patient.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37450.04","spread":"16877.010"},{"groupId":"OG001","value":"36865.81","spread":"19756.050"}]}]}]},{"type":"SECONDARY","title":"Natalizumab Trough Concentration (Ctrough) Over Time, Week 48","description":"Natalizumab trough concentration (Ctrough) over time, week 48. Serum samples were collected prior to treatment. Sample was taken prior to treatment for each patient.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39097.58","spread":"16801.710"},{"groupId":"OG001","value":"38432.86","spread":"16495.407"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Without New/Enlarging T2-weighted Lesions Over 24 Weeks","description":"Number of patients without new/enlarging T2-weighted lesions over 24 weeks. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of T2-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"18","spread":null},{"groupId":"OG004","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Without New/Enlarging T2-weighted Lesions Over 48 Weeks","description":"Number of patients without new/enlarging T2-weighted lesions over 48 weeks. Assessment of lesions was performed using Magnetic Resonance Imaging (MRI). Identification of T2-weighted lesions was done by a trained and certified radiology reviewer according to standard procedures at the MRI central reading center.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"69","spread":null},{"groupId":"OG003","value":"17","spread":null},{"groupId":"OG004","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Abnormal Clinical Laboratory Tests at Week 24","description":"Number of patients with abnormal clinical laboratory tests at week 24.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Abnormal Clinical Laboratory Tests at Week 48","description":"Number of patients with abnormal clinical laboratory tests at week 48.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Abnormal Findings in Physical Examination at Week 24","description":"Number of patients with abnormal findings in physical examination at week 24.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Abnormal Findings in Physical Examination at Week 48","description":"Number of patients with abnormal findings in physical examination at week 48.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Pressure at Week 24","description":"Change from baseline in diastolic and systolic blood Pressure at week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"7.30"},{"groupId":"OG001","value":"-0.6","spread":"7.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"9.76"},{"groupId":"OG001","value":"-1.5","spread":"11.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Pressure at Week 48","description":"Change from baseline in diastolic and systolic blood Pressure at week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"7.58"},{"groupId":"OG001","value":"1.8","spread":"8.16"},{"groupId":"OG002","value":"0.8","spread":"7.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"8.67"},{"groupId":"OG001","value":"2.4","spread":"12.38"},{"groupId":"OG002","value":"3.0","spread":"10.18"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Heart Rate at Week 24","description":"Change from baseline in heart rate at week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"9.05"},{"groupId":"OG001","value":"-1.4","spread":"9.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Heart Rate at Week 48","description":"Change from baseline in heart rate at week 48.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"7.07"},{"groupId":"OG001","value":"1.7","spread":"10.53"},{"groupId":"OG002","value":"1.1","spread":"9.66"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":161},"commonTop":["Headache","Nasopharyngitis","COVID-19","Back pain","Oropharyngeal pain"]}}}